Cargando…
Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced‐stage ovarian cancer
The aim of this study was to investigate the prognostic significance of lymphocytopenia in advanced‐stage ovarian cancer. We retrospectively reviewed 506 patients with advanced‐stage ovarian cancer at Yonsei Cancer Hospital. This study included two cohorts of patients: a neoadjuvant chemotherapy (NA...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382732/ https://www.ncbi.nlm.nih.gov/pubmed/30652425 http://dx.doi.org/10.1002/cam4.1956 |
_version_ | 1783396704017448960 |
---|---|
author | Lee, Yong Jae Chung, Young Shin Lee, Jung‐Yun Nam, Eun Ji Kim, Sang Wun Kim, Sunghoon Kim, Young Tae |
author_facet | Lee, Yong Jae Chung, Young Shin Lee, Jung‐Yun Nam, Eun Ji Kim, Sang Wun Kim, Sunghoon Kim, Young Tae |
author_sort | Lee, Yong Jae |
collection | PubMed |
description | The aim of this study was to investigate the prognostic significance of lymphocytopenia in advanced‐stage ovarian cancer. We retrospectively reviewed 506 patients with advanced‐stage ovarian cancer at Yonsei Cancer Hospital. This study included two cohorts of patients: a neoadjuvant chemotherapy (NAC) group (N = 247) and a primary debulking surgery (PDS) group (N = 259). The absolute lymphocyte count was recorded before treatment. A receiver operating characteristic (ROC) curve analysis was used to determine the cutoff for defining lymphocytopenia in the NAC cohort and followed by multivariate analysis. Subsequently, lymphocytopenia was assessed in the PDS cohort by multivariate analysis. A further analysis was performed to evaluate the absolute lymphocyte count as a continuous variable. An absolute lymphocyte count of 1.49 × 109/L was determined as the cutoff for the ROC curve analysis in the NAC cohort, and the multivariate analysis revealed that lymphocytopenia was an independent prognostic factor for poor progression‐free survival (PFS) [hazard ratio (HR), 1.50; 95% confidence interval (CI), 1.07‐2.11] and overall survival (OS) (HR, 2.02; 95% CI, 1.21‐3.40). In the PDS cohort, the multivariate analysis showed that lymphocytopenia was an independent prognostic factor for poor PFS (HR, 1.73; 95% CI, 1.20‐2.49) and OS (HR, 1.87; 95% CI, 1.27‐2.75). The absolute lymphocyte count was a significant factor when analyzed as a continuous variable in both the NAC and PDS cohorts. Pretreatment lymphocytopenia is an independent adverse prognostic factor in patients with advanced‐stage ovarian cancer. |
format | Online Article Text |
id | pubmed-6382732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63827322019-03-01 Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced‐stage ovarian cancer Lee, Yong Jae Chung, Young Shin Lee, Jung‐Yun Nam, Eun Ji Kim, Sang Wun Kim, Sunghoon Kim, Young Tae Cancer Med Clinical Cancer Research The aim of this study was to investigate the prognostic significance of lymphocytopenia in advanced‐stage ovarian cancer. We retrospectively reviewed 506 patients with advanced‐stage ovarian cancer at Yonsei Cancer Hospital. This study included two cohorts of patients: a neoadjuvant chemotherapy (NAC) group (N = 247) and a primary debulking surgery (PDS) group (N = 259). The absolute lymphocyte count was recorded before treatment. A receiver operating characteristic (ROC) curve analysis was used to determine the cutoff for defining lymphocytopenia in the NAC cohort and followed by multivariate analysis. Subsequently, lymphocytopenia was assessed in the PDS cohort by multivariate analysis. A further analysis was performed to evaluate the absolute lymphocyte count as a continuous variable. An absolute lymphocyte count of 1.49 × 109/L was determined as the cutoff for the ROC curve analysis in the NAC cohort, and the multivariate analysis revealed that lymphocytopenia was an independent prognostic factor for poor progression‐free survival (PFS) [hazard ratio (HR), 1.50; 95% confidence interval (CI), 1.07‐2.11] and overall survival (OS) (HR, 2.02; 95% CI, 1.21‐3.40). In the PDS cohort, the multivariate analysis showed that lymphocytopenia was an independent prognostic factor for poor PFS (HR, 1.73; 95% CI, 1.20‐2.49) and OS (HR, 1.87; 95% CI, 1.27‐2.75). The absolute lymphocyte count was a significant factor when analyzed as a continuous variable in both the NAC and PDS cohorts. Pretreatment lymphocytopenia is an independent adverse prognostic factor in patients with advanced‐stage ovarian cancer. John Wiley and Sons Inc. 2019-01-16 /pmc/articles/PMC6382732/ /pubmed/30652425 http://dx.doi.org/10.1002/cam4.1956 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Lee, Yong Jae Chung, Young Shin Lee, Jung‐Yun Nam, Eun Ji Kim, Sang Wun Kim, Sunghoon Kim, Young Tae Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced‐stage ovarian cancer |
title | Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced‐stage ovarian cancer |
title_full | Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced‐stage ovarian cancer |
title_fullStr | Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced‐stage ovarian cancer |
title_full_unstemmed | Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced‐stage ovarian cancer |
title_short | Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced‐stage ovarian cancer |
title_sort | pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced‐stage ovarian cancer |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382732/ https://www.ncbi.nlm.nih.gov/pubmed/30652425 http://dx.doi.org/10.1002/cam4.1956 |
work_keys_str_mv | AT leeyongjae pretreatmentlymphocytopeniaisanadverseprognosticbiomarkerinadvancedstageovariancancer AT chungyoungshin pretreatmentlymphocytopeniaisanadverseprognosticbiomarkerinadvancedstageovariancancer AT leejungyun pretreatmentlymphocytopeniaisanadverseprognosticbiomarkerinadvancedstageovariancancer AT nameunji pretreatmentlymphocytopeniaisanadverseprognosticbiomarkerinadvancedstageovariancancer AT kimsangwun pretreatmentlymphocytopeniaisanadverseprognosticbiomarkerinadvancedstageovariancancer AT kimsunghoon pretreatmentlymphocytopeniaisanadverseprognosticbiomarkerinadvancedstageovariancancer AT kimyoungtae pretreatmentlymphocytopeniaisanadverseprognosticbiomarkerinadvancedstageovariancancer |